Key Factors Associated with First-Line and Maintenance Therapy Prescription Frequency

Video

A look at the key factors associated with 1L and 1LM therapy prescription frequency in the PARADIGM study.

Recent Videos
Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Updated findings from the phase 3 EV-302 trial show enduring responses and survival improvements with enfortumab vedotin plus pembrolizumab.
Karine Tawagi, MD, and Sia Daneshmand, MD, with the Oncology Brothers presenting slides
Related Content
FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

FDA Approves Adjuvant Durvalumab/Chemo in Muscle-Invasive Bladder Cancer

Ariana Pelosci
March 28th 2025
Article

Results from the phase 3 NIAGARA trial led to the approval of adjuvant durvalumab/chemotherapy for patients with muscle-invasive bladder cancer after radical cystectomy.

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

NIAGARA Study is the Forefront of Post-ASCO GU Discussion in Bladder Cancer

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Petros Grivas, MD, PhD;David Morris, MD, MS
March 4th 2025
Podcast

The Oncology Decoded podcast highlighted the impact of the results from the NIAGARA trial for patients with bladder cancer in a post-ASCO GU discussion.

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

Tim Cortese
March 11th 2025
Article

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

Matthew Fowler;Jun Gong, MD
March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

EV-302 Supports Enfortumab Vedotin Plus Pembrolizumab as Bladder Cancer SOC

Russ Conroy
February 25th 2025
Article

Outcomes observed in the phase 3 EV-302 trial are “transformative” for most patients with advanced or metastatic urothelial carcinoma.

Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

Durable Responses in Low-Grade, Intermediate-Risk NMIBC with UGN-102

Ashling Wahner
February 15th 2025
Article

Data from the ENVISION and ATLAS trials demonstrated clinically meaningful responses with UGN-102 in the treatment of low-grade, intermediate-risk NMIBC.